Keith Couper, Chen Ji, Ranjit Lall, Charles D Deakin, Rachael Fothergill, John Long, James Mason, Felix Michelet, Jerry P Nolan, Henry Nwankwo, Tom Quinn, Anne-Marie Slowther, Michael A Smyth, Alison Walker, Loraine Chowdhury, Chloe Norman, Laurille Sprauve, Kath Starr, Sara Wood, Steve Bell, Gemma Bradley, Martina Brown, Shona Brown, Karl Charlton, Alison Coppola, Charlotte Evans, Christine Evans, Theresa Foster, Michelle Jackson, Justin Kearney, Nigel Lang, Adam Mellett-Smith, Ria Osborne, Helen Pocock, Nigel Rees, Robert Spaight, Belinda Tibbetts, Gregory A Whitley, Jason Wiles, Julia Williams, Adam Wright, Gavin D Perkins
AIMS: The PARAMEDIC-3 trial evaluates the clinical and cost-effectiveness of an intraosseous first strategy, compared with an intravenous first strategy, for drug administration in adults who have sustained an out-of-hospital cardiac arrest. METHODS: PARAMEDIC-3 is a pragmatic, allocation concealed, open-label, multi-centre, superiority randomised controlled trial. It will recruit 15,000 patients across English and Welsh ambulance services. Adults who have sustained an out-of-hospital cardiac arrest are individually randomised to an intraosseous access first strategy or intravenous access first strategy in a 1:1 ratio through an opaque, sealed envelope system...
March 2024: Resuscitation plus